Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Clinical trial NCT06107790 · COMPLETED
Trial details
- NCT number
- NCT06107790
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-16
- Primary completion
- 2022-01-28
- Enrollment
- 570
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.